The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Esin R.G.

Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education;
Kazan (Volga Region) Federal University

Khayrullin I.Kh.

Kazan (Volga region) Federal University

Esin O.R.

Kazan (Volga region) Federal University;
Clinic of Otorhinolaryngology

Diabetic encephalopathy: current insights and potential therapeutic strategies

Authors:

Esin R.G., Khayrullin I.Kh., Esin O.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7): 49‑54

DOI: 10.17116/jnevro202112107149

Read: 5294 times

Download PDF (RU)
Contact the author
Table of contents

DIABETIC ENCEPHALOPATHY: CURRENT INSIGHTS AND POTENTIAL THERAPEUTIC STRATEGIES
DIABETIC ENCEPHALOPATHY: CURRENT INSIGHTS AND POTENTIAL THERAPEUTIC STRATEGIES

To cite this article:

Esin RG, Khayrullin IKh, Esin OR. Diabetic encephalopathy: current insights and potential therapeutic strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7):49‑54. (In Russ.)
https://doi.org/10.17116/jnevro202112107149

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Effe­cts of sema­glutide on mental health. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):28-36
Move­ment image training and brain-computer inte­rface in cognitive reha­bilitation. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):27-35
Classification, diagnosis and therapy of atte­ntion defi­cit hype­ractivity diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):62-68
The effect of psychopharmacological load on various aspe­cts of the condition in patients with depressive syndrome during remi­ssion. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):69-76
Ethnic aspe­cts of risk factors for the type 2 diabetes mellitus deve­lopment in the overweight women of the Pribaikalsky region. Russian Journal of Preventive Medi­cine. 2025;(8):56-62
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
Possibilities of oral form of cyanocobalamin in pharmacological correction of vita­min B12 defi­ciency deve­loped in patients with type 2 diabetes mellitus during treatment with metformin. Russian Journal of Preventive Medi­cine. 2025;(9):64-69
Rela­tionship between heart rate and patients with type 2 diabetes death. Russian Journal of Preventive Medi­cine. 2025;(11):14-22
Abstract:

OBJECTIVE

To study the effect of alpha-lipoic acid (ALA) on cognitive functions in patients with non-insulin dependent diabetes mellitus type 2 (DM-2) and thick fiber polyneuropathy.

MATERIAL AND METHODS

The MoCA test was used to assess cognitive functions, and vibrometry («Somedic» vibrometer) was used to assess the function of thick fibers. Patients in group 1 (n=37) received alpha lipoic acid (ALA) in a dose of 600 mg per day for 16 weeks, patients in group 2 (n=41) started taking ALA 8 weeks after the start of the study.

RESULTS

Comparison of both groups showed an increase in the indicators of the MoCA test in group 1 after 8 weeks (p=0.0025) with a further plateau and an improvement in vibration sensitivity after 16 weeks (p=0.023). The improvement in the MoCA test in group 2 also began after 8 weeks.

CONCLUSION

The authors recommend ALA in polyneuropathy as a drug that also has a positive effect on cognitive functions in DM-2 and dipyridamole for the treatment of patients with diabetic encephalopathy and cerebral small vessels disease and stroke.

Keywords:

type 2 diabetes mellitus
encephalopathy
dipyridamole
alpha lipoic acid
cognitive function

Authors:

Esin R.G.

Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education;
Kazan (Volga Region) Federal University

Khayrullin I.Kh.

Kazan (Volga region) Federal University

Esin O.R.

Kazan (Volga region) Federal University;
Clinic of Otorhinolaryngology

Received:

27.01.2021

Accepted:

11.02.2021

Close metadata

References:

  1. Diabetes. Accessed Dec 01, 2020. https://www.who.int/news-room/fact-sheets/detail/diabetes
  2. Khairullin IKh, Esin RG, Pozdniak AO. Cognitive impairment in patients with diabetes mellitus type 2 and possibilities of its treatment. Zh Nevrol Psikhiatr Im SS Korsakova. 2014;114(9):25-29. (In Russ.). PMID: 25403297.
  3. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222. https://doi.org/10.1016/S0140-6736(10)60484-9
  4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64-74.  https://doi.org/10.1016/S1474-4422(05)70284-2
  5. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701.  https://doi.org/10.1016/S1474-4422(10)70104-6
  6. Liu J, Rutten-Jacobs L, Liu M, Markus HS, Traylor M. Causal Impact of Type 2 Diabetes Mellitus on Cerebral Small Vessel Disease. Stroke. 2018;49(6):1325-1331. https://doi.org/10.1161/STROKEAHA.117.020536
  7. Fu Y, Yan Y. Emerging Role of Immunity in Cerebral Small Vessel Disease. Front Immunol. 2018;9:67.  https://doi.org/10.3389/fimmu.2018.00067
  8. Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci (Lond). 2017;131(17):2257-2274. https://doi.org/10.1042/CS20160381
  9. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-696.  https://doi.org/10.1016/S1474-4422(19)30079-1
  10. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. Stroke Vasc Neurol. 2016;1(3):83-92.  https://doi.org/10.1136/svn-2016-000035
  11. Ramakers BP, Riksen NP, Stal TH, Heemskerk S, van den Broek P, Peters WH, van der Hoeven JG, Smits P, Pickkers P. Dipyridamole augments the antiinflammatory response during human endotoxemia. Crit Care. 2011;15(6):R289. https://doi.org/10.1186/cc10576
  12. Georgakis MK, Dimitriou NG, Karalexi MA, Mihas C, Nasothimiou EG, Tousoulis D, Tsivgoulis G, Petridou ET. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2017;65(6):1190-1198. https://doi.org/10.1111/jgs.14750
  13. Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol. 2002;36(2):145-148.  https://doi.org/10.1080/003655902753679454
  14. Elsherbiny NM, Al-Gayyar MMH, Abd El Galil KH. Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. Life Sciences. 2015;143:8-17.  https://doi.org/10.1016/j.lfs.2015.10.026
  15. Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus — Associated Chronic Inflammation. The J Infect Dis. 2020;221(10):1598-1606. https://doi.org/10.1093/infdis/jiz344
  16. d’Esterre CD, Lee TY. Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits. Ann NY Acad Sci. 2010;1207:71-75.  https://doi.org/10.1111/j.1749-6632.2010.05801.x
  17. Guo S, Stins M, Ning M, Lo EH. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis. 2010;30(3):290-296.  https://doi.org/10.1159/000319072
  18. Zhang JJ, Liu X. Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. Medicine (Baltimore). 2018;97(13):e0123. https://doi.org/10.1097/MD.0000000000010123
  19. Dipyridamole Drug Interactions. Accessed Dec 01, 2020. https://www.drugs.com/drug-interactions/dipyridamole.html
  20. Clopidogrel Drug Interactions. Accessed Dec 01, 2020. https://www.drugs.com/drug-interactions/clopidogrel.html
  21. Aspirin Drug Interactions. Accessed Dec 01, 2020. https://www.drugs.com/drug-interactions/aspirin.html
  22. Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C, Ermio C, De Bartolo M, Mauro G, Bosco D. The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer’s Disease. J Neurodegener Dis. 2013;2013:454253. https://doi.org/10.1155/2013/454253
  23. Molz P, Schröder N. Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration. Front Pharmacol. 2017;8:849.  https://doi.org/10.3389/fphar.2017.00849
  24. Triggiani L. Potential therapeutic effects of alpha lipoic acid in memory disorders. Progress in Nutrition. 2020;22(1):12-19.  https://doi.org/10.23751/pn.v22i1.9341
  25. Della Giustina A, Goldim MP, Danielski LG, Florentino D, Mathias K, Garbossa L, Oliveira Junior AN, Fileti ME, Zarbato GF, da Rosa N, Martins Laurentino AO, Fortunato JJ, Mina F, Bellettini-Santos T, Budni J, Barichello T, Dal-Pizzol F, Petronilho F. Alpha-lipoic acid attenuates acute neuroinflammation and long-term cognitive impairment after polymicrobial sepsis. Neurochem Int. 2017;108:436-447.  https://doi.org/10.1016/j.neuint.2017.06.003
  26. Esin RG, Khairullin IK, Esin OR. Cerebral insulin resistance: current concepts of the pathogenesis and possible therapeutic strategies. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(1):92-95. (In Russ.). https://doi.org/10.17116/jnevro20181181192-95
  27. Esin R, Gorobets E, Esin O, Khayrullin I, Gorobets V, Volskaya Y. The Comorbidity of Back and Cervical Pain, Anxiety, Depression and Alexitymia. BioNanoScience. 2020;10(1):365-369.  https://doi.org/10.1007/s12668-019-00714-z
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.